Svenja Nölting, MD

Professor Dr. Svenja Nölting is a board-certified endocrinologist, Assistant Professor for Endocrine Tumors, and joint Leader of the Neuroendocrine Tumor Board and the Endocrine and Neuroendocrine Tumor Center, ENETS Center of Excellence Zurich, at the Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital of Zurich, USZ, and the University of Zurich, UZH. After she finished her medicine studies in 2008 and her doctoral thesis in 2009 at the LMU Munich, she started her training as Medical Doctor (MD) at the Medical Department II of the University Hospital of the LMU Munich. In 2010 she received a DFG (Deutsche Forschungsgemeinschaft, German Research Foundation) research grant for investigating novel targeted drugs in malignant pheochromocytomas and paragangliomas, and held a post-doctoral position at Barts and the London School of Medicine (mentor Ashley Grossman), and at the NIH, Bethesda, Maryland, USA (mentor Karel Pacak) from 2010–2012. She then continued her training as MD at the Medical Departments II and IV of the University Hospital of the LMU Munich, becoming Research Group Leader with a special interest in personalized therapy of (Neuro)endocrine Tumors in 2012. In 2020 she was appointed Assistant Professor for Endocrine Tumors at the USZ and UZH. Prof. Nölting has become one of the most respected international experts in the field of pheochromocytoma and paraganglioma research and therapy. Her research has been funded amongst others by the DFG (Deutsche Forschungsgemeinschaft, German Research Foundation), Wilhelm Sander-Stiftung and Else Kröner-Fresenius-Stiftung. She is the author of more than 70 scientific peer-reviewed articles, mainly in the field of pheochromocytomas and paragangliomas. In 2022, she received the ENSAT Award for her pheochromocytoma and paraganglioma research, and the Rising Star Award of the European Journal of Endocrinology. She serves as member of the scientific committee of the International Symposium on Pheochromocytoma 2025.